uniQure Pharma (QURE) Long-Term Debt to Capital Ratio

This price chart for uniQure N.V. (QURE), which assists in the basic asset valuation, illustrates the price action of the genetic medicine developer. The current metric stands at 1.59, correlating with the planned expenditure on costly research. Meanwhile, the business relies on payments from commercialized products and a diverse portfolio of clinical projects that mitigate risks. The development vector is focused on the commercialization of the AAV platform and expansion into the field of cardiac and neurological pathologies.

This indicator assesses the ratio of long-term liabilities to equity, determining the degree of financial autonomy and the risk of excessive borrowing for business development. By analyzing the long-term debt financial leverage ratio, an investor can see how stable royalties from hemophilia gene therapy allow uniQure N.V. (QURE) to maintain a sustainable balance between debt load and equity, thereby minimizing the risks of clinical failures.